Preterm birth is also referred as premature birth of a baby. Preterm birth is considered when a baby is born fewer than 37 weeks gestational age. These babies are known as preemies or premmies. A developing baby undergoes through crucial growth process throughout the pregnancy including the final month. During the last month of pregnancy the brain, lungs, and liver fully develops. If babies are born too early than the desired time period of pregnancy, it creates high chances the disability for the baby. Preterm birth is sub-categories in three stages based on gestational age viz. extremely preterm (less than 28 weeks), very preterm (28 to 32 weeks), moderate to late preterm (32 to 37 weeks). Preterm birth occurs due to various reasons but the multiple pregnancies, infections and chronic conditions such as diabetes and high blood pressure are the common cause of preterm birth. Some cause of preterm birth might be the genetic influence and some are still unidentified.
Preterm Birth Prevention and Management Market: Drivers and Restraints
WHO has estimated that every year 15 million babies are born preterm which is the primary factor responsible for the growth of preterm prevention and management market. Preterm birth is also the leading cause of death among the children under 5 years of age, responsible for approximately 1 million deaths in 2015. Beside than increasing awareness by various NGO about women healthcare during the pregnancy will propel the growth of preterm birth prevention and management market. Hospitals are frequently organizing awareness programme to use the Progesterone Supplementation to avoid the premature delivery will also boost the growth of preterm birth prevention and management market. Stringent regulatory scenario for the drug approval to treat the pregnant women will deter the growth of preterm birth prevention and management market to some extent.
Preterm Birth Prevention and Management Market: Overview
Preterm Birth Prevention and Management market is expected show exponential growth over the forecast owing to rising incidences of premature birth. According to WHO, the rate of preterm birth ranges from 5% to 18% of babies born across the 184 countries throughout the globe. Among all the preterm birth, 60% of cases happen only in South Asia and Africa but preterm birth is actually a global issue. More than 90% of extremely preterm babies born in low-income countries die within the first few days of life; yet less than 10% of extremely preterm babies die in high-income settings. In 2015, WHO has developed new guidelines with recommendations for improving outcomes of preterm births. By treatment type, Progesterone Supplementation is expected to gain more traction for Preterm Birth Prevention and Management market over the forecast period. Among all distribution channel hospital pharmacies expected to gain maximum market share for Preterm Birth Prevention and Management market.
For Information On The Research Approach Used In The Report, Ask Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-6457
PRETERM BIRTH PREVENTION AND MANAGEMENT MARKET TAXONOMY
The market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
Therapy Type
- Progesterone Therapy
- Corticosteroid Therapy
- Tocolytics Therapy
- Antihypertensive Therapy
- Magnesium Sulfate Therapy
- Heparin Prophylaxis Therapy
- Low-Dose Aspirin Therapy
- Antibiotics Therapy
Route of Administration
- Oral
- Parenteral
- Vaginal
Patient Type
- Prior Spontaneous PTB
- Preeclampsia
- Short Cervix
- Chronic Hypertension
- Insulin-dependent
- Twins
- Antiphospholipid Antibody Syndrome
- Others
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Mail Order Pharmacies
Region
- North America
- Europe
- Latin America
- South Asia
- East Asia
- Oceania
- Middle East And Africa
For Information On The Research Approach Used In The Report, Request TOC@ https://www.futuremarketinsights.com/toc/rep-gb-6457
About FMI
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Contact
Mr. Abhishek Budholiya
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: [email protected]
For Media Enquiries: [email protected]
Website: https://www.futuremarketinsights.com
The global preterm birth prevention and management market surpassed the valuation of US$ 1 Bn in 2019, with growth projected to see a robust CAGR of more than 9% through 2029.
The preterm birth prevention drugs industry is observing a substantial surge in number of FDA-approved new generic copies of blockbuster drugs every year.
This can be primarily attributed to favorable government policy framework and demographics, orphan drug designations, adoption of new combination therapies, and complications in the selection of one line of therapy.Key Takeaways of the StudyDevelopment of higher complexity specific portfolios and consistent focus on areas of strength while working pipelines are the cornerstone for success in the preterm birth prevention market space.Ensuring preterm interventions and research given proportional focus, so funding is aligned with health burden to curb the mortality rateMakena, with various approvals for the treatment of preterm birth in potential female patient pool, contributed to the dominance of the progesterone therapy segment by therapy type in 2018 and continue to do so during the forecast period.Highly effective therapies with cost advantage over are expected to generate significant revenue in the long run.Majority of the global preterm birth cases have not been directed towards preterm diagnostic leading to higher mortality rates and complicationsSale of Hydroxyprogesterone over antihypertensive drugs such as Nifedipine, and labetalol in the global preterm birth prevention and management market has increased drastically owing to quicker onset of action and higher efficacy.The demand from high preterm birth rate countries, development of new drug entity, loss of exclusivity in hydroxyprogesterone, and growth strategies based on tie up with distribution channel partners are projected to offer new growth opportunities for the preterm birth prevention and management market.Request For Report Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-6457Launch of Cost-effective Therapies Bodes Well for MarketNew revenue opportunities in developed economies, and orphan drug designation by FDA are contributing significantly towards the launch of cost-effective therapies.
A few other factors assisting the growth of preterm birth prevention and management market include adoption of preterm diagnostic tests and the economic burden of premature birth on the system.Frequent drug shortages and unavailability of life-saving formulations in many parts of the country, growing initiatives by government and manufacturers for supply of life-saving preterm birth drugs, particularly in low income and developing countries, are driving the market growth.Strategic Acquisitions by Key Players to Widen Regional PresenceThe leading players in the preterm birth prevention and management market such as AMAG Pharmaceuticals, Pfizer Inc., and Mylan, are concentrating on organic revenue growth and commercial expansions by mergers and distribution agreements and capturing the untapped potential of the preterm birth prevention and management market.In 2019, AMAG Pharmaceuticals, Inc. a largest preterm birth prevention and management drug manufacturer announced the completion of acquisition of Perosphere Pharmaceuticals Inc., a private biopharmaceutical firm.
This acquisition further strengthened AMAG Pharmaceuticals hold of preterm birth prevention and management business with addition of heparin therapyAMAG acquired the global rights to R and marketing of digoxin immune Fab, a drug used to treat severe preeclampsia in pregnant women from Velo Bio, LLC.More Valuable Insights on Preterm birth prevention and management MarketFuture Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the segments from 2014 to 2029.
The global preterm birth prevention and management market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.The study provide compelling insights on preterm birth prevention and management market on basis of therapy type (progesterone therapy, corticosteroid therapy, tocolytics therapy, antihypertensive therapy, magnesium sulfate therapy, heparin prophylaxis therapy, low-dose aspirin therapy, and antibiotics therapy) and by route of administration (Oral, Parenteral, and Vaginal) , and by patient type (prior spontaneous PTB, preeclampsia, short cervix, chronic hypertension, insulin-dependent, twins, antiphospholipid antibody syndrome, and others) and by distribution channel (hospital pharmacies, retail pharmacies, drug stores, and mail order pharmacies), across seven major regions.Speak to Analyst, Questions Related To Report @ https://www.futuremarketinsights.com/ask-question/rep-gb-6457Reasons to Buy the reportWe provide authentic and detailed an analysis on various market trends to enable businesses to make informed and beneficial decisions to attain competitive edge over key players.Our analysts provide detailed market segmentation along with meaningful insights and extensive reports that other companies fail to include.The report includes accurate analysis of the market and the current developing trends affecting the growth.
The Preterm Birth And PROM Testing Market research report provides the latest industry data, growth, key segments and future trends on the basis of the detailed study.
This market report also allows you to identify the future opportunity and growth rate of the leading segment based on regions and countriesThe research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the preterm birth and PROM testing market include Abbott Laboratories, Biosynex, Clinical Innovations, LLC, Cooper Companies, Inc., Hologic, Inc., IQ Products, Medix Biochemica, NX Prenatal, Inc., QIAGEN, and Sera Prognostics, Inc.
This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Preterm Birth And PROM Testing Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/preterm-birth-and-prom-testing-market/download-sampleMarket DynamicsThe increasing number of preterm births due to the rising average number of women being pregnant is primarily driving the market growth.
The rising various health issues such as diabetes and high blood pressure among women is also fuelling the demand for preterm birth and PROM testing.
However, the availability of alternative diagnostic options such as ultrasound, transvaginal scan, uterine monitoring, and lab tests are likely to hamper the market growth.
